Novel quantification method for psilocin in brain tissues using liquid chromatography-tandem mass spectrometry.
Amir Khajavinia, Jordan Reekie, Déborah Michel, Robert B. Laprairie, Anas El‐aneed
Analytical Methods November 18, 2026 DOI: 10.1039/d6ay01614f (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Method development and validation study with in vivo mouse comparison Peer reviewed |
|---|---|
| Population | Mouse brain tissue |
| Interventions | Psilocybin Psilocin-psilocybin co-crystal formulation |
| Topics | Psilocybin |
| Key points | The validated LC-MS/MS method achieved a lower limit of quantification of 0.05 ng mL-1 for psilocin in mouse brain tissue. Psilocybin-treated mice had higher brain psilocin concentrations at 10 minutes than co-crystal-treated mice, while co-crystal administration appeared to yield more sustained concentrations, a difference that was not statistically significant. No sex- or brain-region-dependent differences were found, and 4-HIAA was not detected. |
Abstract
Psilocin, the psychoactive metabolite of psilocybin, is emerging as a therapeutic agent for treatment-resistant depression and anxiety. Precise measurement of psilocin and its major metabolite, 4-hydroxyindole-3-acetic acid (4-HIAA), in the brain tissue is, therefore, essential for characterizing its pharmacokinetics and informing safe, evidence-based use. However, quantitative liquid chromatography-tandem mass spectrometric (LC-MS/MS) analysis of small molecules in brain tissues is challenged by high levels of endogenous phospholipids that can negatively affect peak shape, and residual salts that can suppress ionization, hence compromising method reproducibility. The objective of this study was to develop a new validated LC-MS/MS approach for quantifying psilocin in different brain sections by resolving matrix effects at the chromatographic and instrumental level. In fact, no fully validated LC-MS method currently exist to determine psilocin within its target organ. Rather than relying on sorbent-based phospholipid removal, we implemented a chromatography-centered approach comprising matrix dilution (1 : 9, homogenate : organic), reduced flow with a shallower gradient to separate analytes from phospholipid signals, and precise diverter-valve timing to divert salt-rich LC eluent to waste. These modifications allowed for achieving a 0.05 ng mL-1 lower limit of quantification (LLOQ) using merely a protein precipitation step. In addition, the method met bioanalytical validation criteria for selectivity, accuracy, and precision, enabling reliable quantification in mouse brain tissue. Comparison of psilocybin with a psilocin-psilocybin co-crystal formulation revealed no sex- or brain region-dependent differences in brain psilocin concentrations. Psilocybin-treated mice had higher brain psilocin concentrations at 10 min than co-crystal-treated mice. Co-crystal administration appeared to yield more sustained brain psilocin concentrations, although this difference was not statistically significant compared to the psilocybin group. Under the same experimental conditions, 4-HIAA was not detected, consistent with limited brain accumulation and rapid clearance within the sampled window.
Citations in the library
Cites 8
- Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder JAMA Psychiatry November 4, 2020
- Pharmacokinetics and Pharmacodynamics of Oral Psilocybin Administration in Healthy Participants Clinical Pharmacology & Therapeutics December 12, 2022
- Psilocybin in neuropsychiatry: a review of its pharmacology, safety, and efficacy CNS Spectrums July 11, 2022
- Safety pharmacology of acute psilocybin administration in healthy participants Neuroscience Applied 2024
- Psilocybin reduces alcohol self-administration via selective left nucleus accumbens activation in rats Brain May 4, 2024
and 3 more in the library